Medical information Clinical review pending

Genetic Testing

Thalassemia Beta Trio Prenatal Mutation Detection Test

The Thalassemia Beta Trio Prenatal Mutation Detection Test helps expecting parents identify potential genetic disorders, like thalassemia, in their baby. This test analyzes DNA from both parents and amniotic fluid to screen for over 100 mutations.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: 4 mL (2 mL min.) whole blood in 1 Lavender top (EDTA) tube from both parents; 10 mL (5 mL min.) Amniotic fluid in a sterile screw-capped container.
Results: Results are typically available by Friday, provided samples are submitted by Monday 11 AM. Confirm current turnaround times with the laboratory before booking.
Preparation: No special preparation is required for the parents' blood samples. For the amniotic fluid sample, this procedure is typically performed between 15 and 20 weeks of gestation by a qualified healthcare provider. Confirm specific collection procedures with your doctor.

Test priceKSh 42,120

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Thalassemia Beta Trio Prenatal Mutation Detection Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Expecting parents concerned about thalassemia risk.
✓Family history of thalassemia or related blood disorders.
✓Parents who are known carriers of thalassemia mutations.
✓Couples seeking prenatal genetic screening.
✓Individuals from populations with a higher prevalence of thalassemia.

In plain language

What this test helps you understand

This test provides information about the risk of a fetus inheriting beta thalassemia or related genetic disorders based on the parents' carrier status and fetal DNA analysis. It aids in prenatal diagnosis and management planning.

The Thalassemia Beta Trio Prenatal Mutation Detection Test is a genetic screening tool for expectant parents. It helps identify potential genetic disorders, particularly thalassemia, a blood disorder affecting hemoglobin production, in the fetus. Early detection allows for informed decision-making regarding prenatal care and management. This comprehensive test examines over 100 mutations associated with beta thalassemia and related genetic disorders by analyzing DNA from both parents and the amniotic fluid. We provide accurate information about the genetic health of the fetus. Results are provided in a clear format, and a genetic counselor is available to help interpret them and discuss implications and options. We offer this test across major cities in Kenya.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo special preparation is required for the parents' blood samples. For the amniotic fluid sample, this procedure is typically performed between 15 and 20 weeks of gestation by a qualified healthcare provider. Confirm specific collection procedures with your doctor.

Sample4 mL (2 mL min.) whole blood in 1 Lavender top (EDTA) tube from both parents; 10 mL (5 mL min.) Amniotic fluid in a sterile screw-capped container.

MethodologyDNA extraction followed by molecular analysis (e.g., PCR, sequencing) to detect specific mutations in the HBB gene associated with beta thalassemia.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test screens for a specific panel of over 100 common mutations associated with beta thalassemia. It may not detect all possible mutations. A negative result does not completely rule out the possibility of the disorder. Interpretation of results should be done in consultation with a healthcare professional or genetic counselor.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Thalassemia is an inherited blood disorder that affects the body's ability to produce hemoglobin, the protein in red blood cells that carries oxygen.

It's called a 'Trio' test because it analyzes DNA from both parents and the fetus (via amniotic fluid) to assess the risk of the fetus inheriting the condition.

If the test indicates a risk, a genetic counselor will discuss the results with you in detail, explain the implications, and outline potential management options and further testing if needed.

Insurance coverage varies. Please check with your insurance provider regarding coverage for prenatal genetic testing.

You can book the test by calling or WhatsApping us at +254711564616. Our team will assist you with the process.

A duly filled Prenatal Genetic Testing Consent Form (Form 18) and Genomics Clinical Information Requisition Form (Form 20) must be submitted with the samples.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp